MRNA Moderna Inc.

17.93
+0.15  (+1%)
Previous Close 17.78
Open 17.71
Price To Book 4.43
Market Cap 5,920,166,882
Shares 330,182,202
Volume 530,232
Short Ratio
Av. Daily Volume 1,912,557

NewsSee all news

  1. Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

    mRNA-1944 successfully encoded for functional antibody (CHKV-24) in humans at all dose levels tested (0.1, 0.3 and 0.6 mg/kg) Antibody level predicted to protect against chikungunya infection achieved within hours;

  2. Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

    Vaccination immunized seronegative participants to levels consistent with or above seropositive titers and boosted baseline titers in seropositive participants Vaccine was generally well-tolerated Phase 2 study to

  3. Moderna Appoints Tracey Franklin as Chief Human Resources Officer

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that

  4. Moderna to Host R&D Day on September 12, 2019

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it

  5. Moderna to Present at Upcoming Investor Conferences

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 completed.
VEGF-A(AZD8601)
Myocardial ischemia
Phase 1 completed.
mRNA-2416
Solid tumors, lymphoma
Phase 2 trial has been initiated.
mRNA-4157 (KEYNOTE-942)
Personalized cancer vaccine
Phase 1 completed.
mRNA-1388
Chikungunya vaccine
Phase 1 completed.
mRNA-1851
Influenza vaccine
Phase 1 completed.
mRNA-1440
Influenza vaccine
Phase 1 interim analysis showed antibody titers remained above baseline at all dose levels at seven months.
mRNA-1653
Human Metapneumovirus and Human Parainfluenza Infection (hMPV+PIV3 vaccine)
Phase 2 trial to be initiated soon.
mRNA-1647
CMV vaccine (Cytomegalovirus Infection)
Development has been paused - May 8, 2019.
mRNA-1777
RSV vaccine
Phase 1/2 trial is recruiting.
mRNA-3704
Methylmalonic Acidemia (MMA)
Phase 1 dosing has commenced - noted January 8, 2019.
mRNA-2752
Solid tumors, lymphoma
Phase 1 data released September 12, 2019 noted no significant adverse events were observed at the low and middle doses; infusion-related adverse events were observed at the high dose.
mRNA-1944
Chikungunya Virus Infection
Phase 1 data presented at ASCO June 1, 2019.
mRNA-4650
Autologous Cancer
Phase 1 dosing has commenced - August 7, 2019.
mRNA-1172
RSV vaccine
Phase 1 dosing has commenced - August 7, 2019.
mRNA-5671
KRAS cancer vaccine

Latest News

  1. Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

    mRNA-1944 successfully encoded for functional antibody (CHKV-24) in humans at all dose levels tested (0.1, 0.3 and 0.6 mg/kg) Antibody level predicted to protect against chikungunya infection achieved within hours;

  2. Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

    Vaccination immunized seronegative participants to levels consistent with or above seropositive titers and boosted baseline titers in seropositive participants Vaccine was generally well-tolerated Phase 2 study to

  3. Moderna Appoints Tracey Franklin as Chief Human Resources Officer

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that

  4. Moderna to Host R&D Day on September 12, 2019

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it

  5. Moderna to Present at Upcoming Investor Conferences

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its